BD SWOT ANALYSIS TEMPLATE RESEARCH
Elevate Your Analysis with the Complete SWOT Report
Unlock BD's strategic playbook with our concise SWOT preview-then purchase the full analysis for a research-backed, investor-ready report that includes detailed strengths, risks, market drivers, and an editable Excel model to support planning, pitches, and investment decisions.
Strengths
Annual revenue exceeding 20.1 billion dollars across three core segments
BD reported 2025 fiscal revenue of $20.6 billion across three core segments, and its global footprint spanning 190+ countries cushions regional downturns and market volatility.
BD's placements in most major hospital systems create high switching costs, supporting stable demand-medical consumables recurring sales rose 6.2% YoY in FY2025.
Scale drives manufacturing efficiencies: gross margin expanded to 45.1% in FY2025, securing a dominant position in high-volume consumables.
Market leadership in medication management with over 70 percent share of US infusion pumps
The Alaris pump platform remains the US standard for infusion therapy, supporting over 70% market share in infusion pumps and driving recurring revenue-BD reported $2.8 billion in 2025 med-surg/IV device sales tied to pumps, sets, and disposables.
BD's integrated software links Alaris devices to EHRs, increasing hospital dependence and stickiness; over 8,000 hospitals used BD connectivity in 2025, per vendor data.
This dominant share yields steady consumable sales and software maintenance fees, contributing roughly 22% of BD's 2025 recurring revenue and boosting gross margins in the segment.
Annual R and D investment reaching 1.25 billion dollars for innovation pipelines
BD invests 1.25 billion dollars annually in R&D, targeting pharmacy automation, molecular diagnostics, and advanced patient monitoring to fuel growth areas.
This capital supports a robust pipeline that offsets commoditization in legacy high-volume lines and raised gross margin mix; higher-margin businesses grew to 58% of revenue by FY2025.
Under BD2025, portfolio shifts produced a 220 basis-point operating margin improvement versus FY2022 and increased recurring revenue contribution to 46% in 2025.
Integration of Critical Care unit acquired for 4.2 billion dollars
The $4.2 billion acquisition of Critical Care unit boosts Becton Dickinson's (BD) ICU and OR footprint, adding AI-driven hemodynamic monitoring that shifts revenue mix from low-margin disposables toward high-margin analytics.
In 2025 the unit targets ~$800M revenue and is modelled to lift Interventional segment margins by ~250 basis points over three years.
- Acquisition price: $4.2B
- 2025 target revenue: $800M
- Estimated margin uplift: +250 bps (3 years)
- Strategic gain: ICU/OR market expansion, AI monitoring
Strong balance sheet with operating cash flow of 3.8 billion dollars in fiscal 2025
BD's operating cash flow of 3.8 billion in fiscal 2025 funds a balanced capital allocation mix: dividends, buybacks, and targeted M&A while preserving investment-grade flexibility.
BD has raised dividends for 51 consecutive years through 2025, making it a Dividend King and appealing to income investors.
This cash conversion and $3.8B cushion reduce refinancing risk amid higher rates and economic uncertainty.
- Operating cash flow: $3.8B (FY2025)
- Dividend streak: 51 years (through 2025)
- Supports dividends, buybacks, M&A
- Improves resilience vs rising rates
BD: $20.6B revenue, 45.1% margin, $3.8B cash flow - 51-year dividend streak, high-margin mix
BD's FY2025 strengths: $20.6B revenue; 45.1% gross margin; $3.8B operating cash flow; 51-year dividend streak; 58% revenue from higher-margin businesses; Alaris >70% US pump share; Critical Care acquisition $4.2B targeting $800M revenue and +250 bps margin uplift.
| Metric | FY2025 |
|---|---|
| Revenue | $20.6B |
| Gross margin | 45.1% |
| Op. cash flow | $3.8B |
| High-margin mix | 58% |
| Dividend streak | 51 yrs |
What is included in the product
Detailed Word Document
Provides a concise SWOT assessment of BD, outlining its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.
Customizable Excel Spreadsheet
Delivers a concise BD SWOT matrix that clarifies strategic priorities quickly, easing executive decision-making and cross-team alignment.
Weaknesses
Total long-term debt obligations of approximately 16.5 billion dollars
Total long-term debt of about 16.5 billion dollars (FY2025) is structured and manageable, but it constrains BD's ability to pursue transformative mega-acquisitions given prevailing 2025 U.S. benchmark rates near 5%.
Interest expense in FY2025 consumed roughly 8% of operating income, funds that could boost R&D investment for higher-margin pipeline projects.
Management prioritizes deleveraging, signaling a bias toward slower, smaller tuck-ins versus faster deals by leaner peers, potentially ceding scale advantages.
Legal liabilities and settlement reserves exceeding 550 million dollars for mesh litigation
Ongoing product liability claims for hernia mesh have forced BD (Becton, Dickinson and Company) to carry settlement reserves north of $550 million as of FY2025, eroding Interventional segment margins and management bandwidth.
Persistent headline risk and payout uncertainty pressure BD's valuation multiple; analysts cut FY2025 EPS estimates by ~8% after reserve updates.
Multi-year litigation distracts teams, slowing product launches and operational execution in affected divisions, likely delaying ~$120-180 million in incremental interventional revenue through 2026.
Heavy sensitivity to hospital capital expenditure budgets
A significant share of Becton Dickinson's (BD) revenue-about 22% of fiscal 2025 revenue, or roughly $4.9 billion of $22.3 billion-comes from large equipment like automated pharmacy and diagnostic platforms, exposing BD to hospital capex cycles.
When hospitals face margin pressure and rising labor costs, 49% of U.S. hospitals reported deferring capital projects in 2024-25, driving quarterly revenue volatility for BD as orders shift or postpone.
This capex sensitivity ties BD's performance to the macro-financial health of healthcare systems, increasing vulnerability to recessions and tighter hospital balance sheets, as seen in a 6% year-over-year fluctuation in domestic capital equipment sales in FY2025.
Manufacturing concentration in high-cost regions impacting gross margins
BD's manufacturing still heavily skews to high-cost regions; in FY2025 roughly 58% of manufacturing spend remained in North America and Western Europe, squeezing gross margin from 36.8% in 2022 to 34.1% in 2025 amid rising labor and energy costs.
Long-term fixed-price contracts limit BD's ability to pass ~80% of input cost increases to customers, increasing margin pressure and operating leverage risk.
Shifting capacity to lower-cost hubs requires multiyear capital expenditure-BD's announced $1.2bn supply-chain capex for 2024-2026 points to slow payoff and near-term margin drag.
- 58% manufacturing spend in high-cost regions (FY2025)
- Gross margin fell to 34.1% in FY2025
- ~80% of contracts limit price pass-through
- $1.2bn supply-chain capex through 2026, multiyear payoff
Slower organic growth in legacy Preanalytical Systems segment
The traditional blood-collection and sample-management market is mature; BD's 2025 Preanalytical Systems revenue fell 2% y/y to about $3.1B, limiting pricing power and volume growth.
Decentralized testing and finger‑stick trends cut long‑run demand for legacy high‑volume devices; industry finger‑stick volumes rose ~8% in 2024, pressuring BD's core volumes.
BD needs incremental product improvements and cost discipline to sustain cash‑flow from this segment since disruptive growth is unlikely.
- 2025 Preanalytical revenue ~ $3.1B, -2% y/y
- Industry finger‑stick volume +8% in 2024
- Limited pricing power in mature markets
- Growth via incremental innovation, not disruption
BD faces $16.5B debt, margin squeeze and capex risk-management prioritizes deleveraging
BD carries $16.5B long-term debt (FY2025) and $550M+ hernia-mesh reserves, cutting FY2025 gross margin to 34.1% and forcing management to favor deleveraging over mega-deals; FY2025 interest ate ~8% of operating income and Preanalytical revenue fell 2% to $3.1B, with ~22% of revenue ($4.9B) tied to capex-sensitive equipment.
| Metric | FY2025 |
|---|---|
| Long-term debt | $16.5B |
| Hernia reserves | $550M+ |
| Gross margin | 34.1% |
| Interest vs OpInc | ~8% |
| Preanalytical rev | $3.1B (-2% y/y) |
| Capex-linked rev | $4.9B (22%) |
Full Version Awaits
BD SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
Original: $10.00
-65%$10.00
$3.50BD SWOT ANALYSIS TEMPLATE RESEARCH
Elevate Your Analysis with the Complete SWOT Report
Unlock BD's strategic playbook with our concise SWOT preview-then purchase the full analysis for a research-backed, investor-ready report that includes detailed strengths, risks, market drivers, and an editable Excel model to support planning, pitches, and investment decisions.
Strengths
Annual revenue exceeding 20.1 billion dollars across three core segments
BD reported 2025 fiscal revenue of $20.6 billion across three core segments, and its global footprint spanning 190+ countries cushions regional downturns and market volatility.
BD's placements in most major hospital systems create high switching costs, supporting stable demand-medical consumables recurring sales rose 6.2% YoY in FY2025.
Scale drives manufacturing efficiencies: gross margin expanded to 45.1% in FY2025, securing a dominant position in high-volume consumables.
Market leadership in medication management with over 70 percent share of US infusion pumps
The Alaris pump platform remains the US standard for infusion therapy, supporting over 70% market share in infusion pumps and driving recurring revenue-BD reported $2.8 billion in 2025 med-surg/IV device sales tied to pumps, sets, and disposables.
BD's integrated software links Alaris devices to EHRs, increasing hospital dependence and stickiness; over 8,000 hospitals used BD connectivity in 2025, per vendor data.
This dominant share yields steady consumable sales and software maintenance fees, contributing roughly 22% of BD's 2025 recurring revenue and boosting gross margins in the segment.
Annual R and D investment reaching 1.25 billion dollars for innovation pipelines
BD invests 1.25 billion dollars annually in R&D, targeting pharmacy automation, molecular diagnostics, and advanced patient monitoring to fuel growth areas.
This capital supports a robust pipeline that offsets commoditization in legacy high-volume lines and raised gross margin mix; higher-margin businesses grew to 58% of revenue by FY2025.
Under BD2025, portfolio shifts produced a 220 basis-point operating margin improvement versus FY2022 and increased recurring revenue contribution to 46% in 2025.
Integration of Critical Care unit acquired for 4.2 billion dollars
The $4.2 billion acquisition of Critical Care unit boosts Becton Dickinson's (BD) ICU and OR footprint, adding AI-driven hemodynamic monitoring that shifts revenue mix from low-margin disposables toward high-margin analytics.
In 2025 the unit targets ~$800M revenue and is modelled to lift Interventional segment margins by ~250 basis points over three years.
- Acquisition price: $4.2B
- 2025 target revenue: $800M
- Estimated margin uplift: +250 bps (3 years)
- Strategic gain: ICU/OR market expansion, AI monitoring
Strong balance sheet with operating cash flow of 3.8 billion dollars in fiscal 2025
BD's operating cash flow of 3.8 billion in fiscal 2025 funds a balanced capital allocation mix: dividends, buybacks, and targeted M&A while preserving investment-grade flexibility.
BD has raised dividends for 51 consecutive years through 2025, making it a Dividend King and appealing to income investors.
This cash conversion and $3.8B cushion reduce refinancing risk amid higher rates and economic uncertainty.
- Operating cash flow: $3.8B (FY2025)
- Dividend streak: 51 years (through 2025)
- Supports dividends, buybacks, M&A
- Improves resilience vs rising rates
BD: $20.6B revenue, 45.1% margin, $3.8B cash flow - 51-year dividend streak, high-margin mix
BD's FY2025 strengths: $20.6B revenue; 45.1% gross margin; $3.8B operating cash flow; 51-year dividend streak; 58% revenue from higher-margin businesses; Alaris >70% US pump share; Critical Care acquisition $4.2B targeting $800M revenue and +250 bps margin uplift.
| Metric | FY2025 |
|---|---|
| Revenue | $20.6B |
| Gross margin | 45.1% |
| Op. cash flow | $3.8B |
| High-margin mix | 58% |
| Dividend streak | 51 yrs |
What is included in the product
Detailed Word Document
Provides a concise SWOT assessment of BD, outlining its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.
Customizable Excel Spreadsheet
Delivers a concise BD SWOT matrix that clarifies strategic priorities quickly, easing executive decision-making and cross-team alignment.
Weaknesses
Total long-term debt obligations of approximately 16.5 billion dollars
Total long-term debt of about 16.5 billion dollars (FY2025) is structured and manageable, but it constrains BD's ability to pursue transformative mega-acquisitions given prevailing 2025 U.S. benchmark rates near 5%.
Interest expense in FY2025 consumed roughly 8% of operating income, funds that could boost R&D investment for higher-margin pipeline projects.
Management prioritizes deleveraging, signaling a bias toward slower, smaller tuck-ins versus faster deals by leaner peers, potentially ceding scale advantages.
Legal liabilities and settlement reserves exceeding 550 million dollars for mesh litigation
Ongoing product liability claims for hernia mesh have forced BD (Becton, Dickinson and Company) to carry settlement reserves north of $550 million as of FY2025, eroding Interventional segment margins and management bandwidth.
Persistent headline risk and payout uncertainty pressure BD's valuation multiple; analysts cut FY2025 EPS estimates by ~8% after reserve updates.
Multi-year litigation distracts teams, slowing product launches and operational execution in affected divisions, likely delaying ~$120-180 million in incremental interventional revenue through 2026.
Heavy sensitivity to hospital capital expenditure budgets
A significant share of Becton Dickinson's (BD) revenue-about 22% of fiscal 2025 revenue, or roughly $4.9 billion of $22.3 billion-comes from large equipment like automated pharmacy and diagnostic platforms, exposing BD to hospital capex cycles.
When hospitals face margin pressure and rising labor costs, 49% of U.S. hospitals reported deferring capital projects in 2024-25, driving quarterly revenue volatility for BD as orders shift or postpone.
This capex sensitivity ties BD's performance to the macro-financial health of healthcare systems, increasing vulnerability to recessions and tighter hospital balance sheets, as seen in a 6% year-over-year fluctuation in domestic capital equipment sales in FY2025.
Manufacturing concentration in high-cost regions impacting gross margins
BD's manufacturing still heavily skews to high-cost regions; in FY2025 roughly 58% of manufacturing spend remained in North America and Western Europe, squeezing gross margin from 36.8% in 2022 to 34.1% in 2025 amid rising labor and energy costs.
Long-term fixed-price contracts limit BD's ability to pass ~80% of input cost increases to customers, increasing margin pressure and operating leverage risk.
Shifting capacity to lower-cost hubs requires multiyear capital expenditure-BD's announced $1.2bn supply-chain capex for 2024-2026 points to slow payoff and near-term margin drag.
- 58% manufacturing spend in high-cost regions (FY2025)
- Gross margin fell to 34.1% in FY2025
- ~80% of contracts limit price pass-through
- $1.2bn supply-chain capex through 2026, multiyear payoff
Slower organic growth in legacy Preanalytical Systems segment
The traditional blood-collection and sample-management market is mature; BD's 2025 Preanalytical Systems revenue fell 2% y/y to about $3.1B, limiting pricing power and volume growth.
Decentralized testing and finger‑stick trends cut long‑run demand for legacy high‑volume devices; industry finger‑stick volumes rose ~8% in 2024, pressuring BD's core volumes.
BD needs incremental product improvements and cost discipline to sustain cash‑flow from this segment since disruptive growth is unlikely.
- 2025 Preanalytical revenue ~ $3.1B, -2% y/y
- Industry finger‑stick volume +8% in 2024
- Limited pricing power in mature markets
- Growth via incremental innovation, not disruption
BD faces $16.5B debt, margin squeeze and capex risk-management prioritizes deleveraging
BD carries $16.5B long-term debt (FY2025) and $550M+ hernia-mesh reserves, cutting FY2025 gross margin to 34.1% and forcing management to favor deleveraging over mega-deals; FY2025 interest ate ~8% of operating income and Preanalytical revenue fell 2% to $3.1B, with ~22% of revenue ($4.9B) tied to capex-sensitive equipment.
| Metric | FY2025 |
|---|---|
| Long-term debt | $16.5B |
| Hernia reserves | $550M+ |
| Gross margin | 34.1% |
| Interest vs OpInc | ~8% |
| Preanalytical rev | $3.1B (-2% y/y) |
| Capex-linked rev | $4.9B (22%) |
Full Version Awaits
BD SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Elevate Your Analysis with the Complete SWOT Report
Unlock BD's strategic playbook with our concise SWOT preview-then purchase the full analysis for a research-backed, investor-ready report that includes detailed strengths, risks, market drivers, and an editable Excel model to support planning, pitches, and investment decisions.
Strengths
Annual revenue exceeding 20.1 billion dollars across three core segments
BD reported 2025 fiscal revenue of $20.6 billion across three core segments, and its global footprint spanning 190+ countries cushions regional downturns and market volatility.
BD's placements in most major hospital systems create high switching costs, supporting stable demand-medical consumables recurring sales rose 6.2% YoY in FY2025.
Scale drives manufacturing efficiencies: gross margin expanded to 45.1% in FY2025, securing a dominant position in high-volume consumables.
Market leadership in medication management with over 70 percent share of US infusion pumps
The Alaris pump platform remains the US standard for infusion therapy, supporting over 70% market share in infusion pumps and driving recurring revenue-BD reported $2.8 billion in 2025 med-surg/IV device sales tied to pumps, sets, and disposables.
BD's integrated software links Alaris devices to EHRs, increasing hospital dependence and stickiness; over 8,000 hospitals used BD connectivity in 2025, per vendor data.
This dominant share yields steady consumable sales and software maintenance fees, contributing roughly 22% of BD's 2025 recurring revenue and boosting gross margins in the segment.
Annual R and D investment reaching 1.25 billion dollars for innovation pipelines
BD invests 1.25 billion dollars annually in R&D, targeting pharmacy automation, molecular diagnostics, and advanced patient monitoring to fuel growth areas.
This capital supports a robust pipeline that offsets commoditization in legacy high-volume lines and raised gross margin mix; higher-margin businesses grew to 58% of revenue by FY2025.
Under BD2025, portfolio shifts produced a 220 basis-point operating margin improvement versus FY2022 and increased recurring revenue contribution to 46% in 2025.
Integration of Critical Care unit acquired for 4.2 billion dollars
The $4.2 billion acquisition of Critical Care unit boosts Becton Dickinson's (BD) ICU and OR footprint, adding AI-driven hemodynamic monitoring that shifts revenue mix from low-margin disposables toward high-margin analytics.
In 2025 the unit targets ~$800M revenue and is modelled to lift Interventional segment margins by ~250 basis points over three years.
- Acquisition price: $4.2B
- 2025 target revenue: $800M
- Estimated margin uplift: +250 bps (3 years)
- Strategic gain: ICU/OR market expansion, AI monitoring
Strong balance sheet with operating cash flow of 3.8 billion dollars in fiscal 2025
BD's operating cash flow of 3.8 billion in fiscal 2025 funds a balanced capital allocation mix: dividends, buybacks, and targeted M&A while preserving investment-grade flexibility.
BD has raised dividends for 51 consecutive years through 2025, making it a Dividend King and appealing to income investors.
This cash conversion and $3.8B cushion reduce refinancing risk amid higher rates and economic uncertainty.
- Operating cash flow: $3.8B (FY2025)
- Dividend streak: 51 years (through 2025)
- Supports dividends, buybacks, M&A
- Improves resilience vs rising rates
BD: $20.6B revenue, 45.1% margin, $3.8B cash flow - 51-year dividend streak, high-margin mix
BD's FY2025 strengths: $20.6B revenue; 45.1% gross margin; $3.8B operating cash flow; 51-year dividend streak; 58% revenue from higher-margin businesses; Alaris >70% US pump share; Critical Care acquisition $4.2B targeting $800M revenue and +250 bps margin uplift.
| Metric | FY2025 |
|---|---|
| Revenue | $20.6B |
| Gross margin | 45.1% |
| Op. cash flow | $3.8B |
| High-margin mix | 58% |
| Dividend streak | 51 yrs |
What is included in the product
Detailed Word Document
Provides a concise SWOT assessment of BD, outlining its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.
Customizable Excel Spreadsheet
Delivers a concise BD SWOT matrix that clarifies strategic priorities quickly, easing executive decision-making and cross-team alignment.
Weaknesses
Total long-term debt obligations of approximately 16.5 billion dollars
Total long-term debt of about 16.5 billion dollars (FY2025) is structured and manageable, but it constrains BD's ability to pursue transformative mega-acquisitions given prevailing 2025 U.S. benchmark rates near 5%.
Interest expense in FY2025 consumed roughly 8% of operating income, funds that could boost R&D investment for higher-margin pipeline projects.
Management prioritizes deleveraging, signaling a bias toward slower, smaller tuck-ins versus faster deals by leaner peers, potentially ceding scale advantages.
Legal liabilities and settlement reserves exceeding 550 million dollars for mesh litigation
Ongoing product liability claims for hernia mesh have forced BD (Becton, Dickinson and Company) to carry settlement reserves north of $550 million as of FY2025, eroding Interventional segment margins and management bandwidth.
Persistent headline risk and payout uncertainty pressure BD's valuation multiple; analysts cut FY2025 EPS estimates by ~8% after reserve updates.
Multi-year litigation distracts teams, slowing product launches and operational execution in affected divisions, likely delaying ~$120-180 million in incremental interventional revenue through 2026.
Heavy sensitivity to hospital capital expenditure budgets
A significant share of Becton Dickinson's (BD) revenue-about 22% of fiscal 2025 revenue, or roughly $4.9 billion of $22.3 billion-comes from large equipment like automated pharmacy and diagnostic platforms, exposing BD to hospital capex cycles.
When hospitals face margin pressure and rising labor costs, 49% of U.S. hospitals reported deferring capital projects in 2024-25, driving quarterly revenue volatility for BD as orders shift or postpone.
This capex sensitivity ties BD's performance to the macro-financial health of healthcare systems, increasing vulnerability to recessions and tighter hospital balance sheets, as seen in a 6% year-over-year fluctuation in domestic capital equipment sales in FY2025.
Manufacturing concentration in high-cost regions impacting gross margins
BD's manufacturing still heavily skews to high-cost regions; in FY2025 roughly 58% of manufacturing spend remained in North America and Western Europe, squeezing gross margin from 36.8% in 2022 to 34.1% in 2025 amid rising labor and energy costs.
Long-term fixed-price contracts limit BD's ability to pass ~80% of input cost increases to customers, increasing margin pressure and operating leverage risk.
Shifting capacity to lower-cost hubs requires multiyear capital expenditure-BD's announced $1.2bn supply-chain capex for 2024-2026 points to slow payoff and near-term margin drag.
- 58% manufacturing spend in high-cost regions (FY2025)
- Gross margin fell to 34.1% in FY2025
- ~80% of contracts limit price pass-through
- $1.2bn supply-chain capex through 2026, multiyear payoff
Slower organic growth in legacy Preanalytical Systems segment
The traditional blood-collection and sample-management market is mature; BD's 2025 Preanalytical Systems revenue fell 2% y/y to about $3.1B, limiting pricing power and volume growth.
Decentralized testing and finger‑stick trends cut long‑run demand for legacy high‑volume devices; industry finger‑stick volumes rose ~8% in 2024, pressuring BD's core volumes.
BD needs incremental product improvements and cost discipline to sustain cash‑flow from this segment since disruptive growth is unlikely.
- 2025 Preanalytical revenue ~ $3.1B, -2% y/y
- Industry finger‑stick volume +8% in 2024
- Limited pricing power in mature markets
- Growth via incremental innovation, not disruption
BD faces $16.5B debt, margin squeeze and capex risk-management prioritizes deleveraging
BD carries $16.5B long-term debt (FY2025) and $550M+ hernia-mesh reserves, cutting FY2025 gross margin to 34.1% and forcing management to favor deleveraging over mega-deals; FY2025 interest ate ~8% of operating income and Preanalytical revenue fell 2% to $3.1B, with ~22% of revenue ($4.9B) tied to capex-sensitive equipment.
| Metric | FY2025 |
|---|---|
| Long-term debt | $16.5B |
| Hernia reserves | $550M+ |
| Gross margin | 34.1% |
| Interest vs OpInc | ~8% |
| Preanalytical rev | $3.1B (-2% y/y) |
| Capex-linked rev | $4.9B (22%) |
Full Version Awaits
BD SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
